Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of repeatable business escalating. We need to find if management conveys that deals, orders, contracts, projects, customers, sites, or programs are individually bigger, broader, or longer than before for the same offering. Let's scan the transcript for any such statements. Management talks about Sysco Your Way program, national sales wins, etc. They mention "winning substantial new business" and "net new customer wins" but do they say the size of each deal is larger? They mention "multi-year contracts" and "strong profit profiles" but not necessarily that the size per contract is escalating. They talk about "Sysco Your Way" being rolled out to neighborhoods, but not that each neighborhood is bigger. They mention acquisitions in Italy, but that's not about same kind of engagements. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size". Management does not seem to describe that. They talk about volume growth, market share gains, but not about the average size of orders or contracts increasing. They mention "net new customer wins" but not that each new customer is larger than previous ones. They mention "national sales team posted an outstanding quarter, winning substantial new business" but no comparison to past sizes. There is no mention of "the largest single piece of business" or "upward drift in deal size". The only thing close is that they are winning multi-year contracts, but that's not necessarily larger than before. They also mention "Sysco Your Way" program exceeding expectations, but not that each new neighborhood is larger. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.